FENSOLVI KIT Drug Patent Profile

✉ Email this page to a colleague

When do Fensolvi Kit patents expire, and when can generic versions of Fensolvi Kit launch?

Fensolvi Kit is a drug marketed by Tolmar and is included in one NDA. There are two patents protecting this drug.

This drug has eleven patent family members in eleven countries.

The generic ingredient in FENSOLVI KIT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fensolvi Kit

A generic version of FENSOLVI KIT was approved as leuprolide acetate by SANDOZ on August 4^th, 1998.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for FENSOLVI KIT?
What are the global sales for FENSOLVI KIT?
What is Average Wholesale Price for FENSOLVI KIT?

Summary for FENSOLVI KIT

International Patents:	11
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FENSOLVI KIT
DailyMed Link:	FENSOLVI KIT at DailyMed

Drug patent expirations by year for FENSOLVI KIT

Pharmacology for FENSOLVI KIT

Drug Class	Gonadotropin Releasing Hormone Receptor Agonist
Mechanism of Action	Gonadotropin Releasing Hormone Receptor Agonists

US Patents and Regulatory Information for FENSOLVI KIT

FENSOLVI KIT is protected by two US patents.

Patents protecting FENSOLVI KIT

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tolmar	FENSOLVI KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	213150-001	May 1, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y		⤷ Sign Up
Tolmar	FENSOLVI KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	213150-001	May 1, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for FENSOLVI KIT

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Tolmar	FENSOLVI KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	213150-001	May 1, 2020	⤷ Sign Up	⤷ Sign Up
Tolmar	FENSOLVI KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	213150-001	May 1, 2020	⤷ Sign Up	⤷ Sign Up
Tolmar	FENSOLVI KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	213150-001	May 1, 2020	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for FENSOLVI KIT

See the table below for patents covering FENSOLVI KIT around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Slovakia	287528		⤷ Sign Up
Germany	60141421		⤷ Sign Up
Austria	296088		⤷ Sign Up
Iceland	6794		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for FENSOLVI KIT

Pharmacology for FENSOLVI KIT

Patents protecting FENSOLVI KIT

Make Better Decisions: Try a trial or see plans & pricing